GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » EBIT

Theratechnologies (TSX:TH) EBIT : C$-9.3 Mil (TTM As of Feb. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies EBIT?

Theratechnologies's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2024 was C$-2.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-9.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Theratechnologies's annualized ROC % for the quarter that ended in Feb. 2024 was -26.99%. Theratechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -360.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Theratechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -8.68%.


Theratechnologies EBIT Historical Data

The historical data trend for Theratechnologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies EBIT Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.94 -22.60 -32.67 -54.23 -18.06

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.80 -10.01 2.86 0.19 -2.33

Competitive Comparison of Theratechnologies's EBIT

For the Biotechnology subindustry, Theratechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theratechnologies's EV-to-EBIT falls into.



Theratechnologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-9.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (TSX:TH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Theratechnologies's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

ROC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-12.128 * ( 1 - -2.52% )/( (45.638 + 46.48)/ 2 )
=-12.4336256/46.059
=-26.99 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Theratechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2023  Q: Feb. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.304/( ( (2.709 + max(-23.891, 0)) + (2.456 + max(-25.03, 0)) )/ 2 )
=-9.304/( ( 2.709 + 2.456 )/ 2 )
=-9.304/2.5825
=-360.27 %

where Working Capital is:

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.542 + 8.315 + 4.514) - (39.025 + 0.052 + 15.185)
=-23.891

Working Capital(Q: Feb. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.495 + 8.509 + 3.631) - (40.547 + 0.051 + 10.067)
=-25.03

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Theratechnologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2024 )
=-9.286/106.935
=-8.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies EBIT Related Terms

Thank you for viewing the detailed overview of Theratechnologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (TSX:TH) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.
Executives
Joseph Arena Director
Philippe Dubuc Senior Officer
Gérald A. Lacoste Director
Paul Lévesque Senior Officer
Andrew Molson Director
Dawn Svoronos Director
John Leasure Senior Officer